What Should I Do, Doc?
“What Should I Do, Doc?” – Archives of Internal Medicine
“What Should I Do, Doc?” – Archives of Internal Medicine
Most people in the United States get health insurance either through their employer or through government programs like Medicare and Medicaid. But some people have to find other ways to get healthcare insurance, with an increasing number of people doing so through the Obamacare exchanges, or “marketplaces.” In fact, according to the Kaiser Family Foundation…
Shutterstock Mark Letterman’s rheumatoid arthritis had been progressing unrelentingly despite popping dozens of pills each week – eight methotrexate pills on Mondays alone. Letterman felt like he was 63 going on 93. If rheumatoid arthritis progresses unchecked, it is as debilitating of a disease as can be imagined. Don’t think garden variety arthritis that only…
Here is the opening of an article I recently published in JAMA, available now online, in which I raise concerns about misguided congressional efforts to promote the use of high-value healthcare services, without doing anything to reduce the use of low value ones. Health care systems around the world are under pressure to restrain health…
Many people consider the randomized control trial the gold standard for assessing medical interventions. The US government has been a major funder of such trials, as illustrated in this picture which shows that the government funds just about as many RCTs as private industry: Despite so much US funding for RCTs, the location of such…
Let me be clear: how long people live in any country of the world is determined by lots of things, not just by the quality of their healthcare system. Nevertheless, one of the things medical care is supposed to do is help us live longer and healthier lives. So you would think that a country…
It is hard to make money treating rare diseases. There simply aren’t enough customers to generate many profits. That’s why the U.S. government passed the Orphan Drug Act in 1983, a law which created a series of incentives to encourage drug companies to develop treatments for rare or “orphan” diseases – conditions affecting less than…